- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Consumer Lawsuits Filed Against Anthem for Denying Harvoni Coverage
Two lawsuits have been filed against Anthem Blue Cross for denying coverage to 2 women for the hepatitis C medication Harvoni.
Two lawsuits have been filed against Anthem Blue Cross for denying coverage to 2 women for the hepatitis C medication Harvoni. Both lawsuits claim the insurer denied coverage for Harvoni, because the amount of liver damage sustained by the women was insufficient to warrant payment for the drug, and the treatment was not medically necessary.
The arguments go back and forth. In its denial letter sent to 1 of the plaintiffs, Anthem said that the women's liver had not yet sustained enough damage. The plaintiff argues that preventing her liver from getting to that stage would be the point of her treatment.
Read the complete report on The Wall Street Journal: http://on.wsj.com/1FUq4Eu
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
